Review by Claire Derlot Head of Programs for LBP Development & Manufacturing A few weeks back, Nadine, Richard, Adrien, and I had the pleasure of attending the Boston-based microbiome drug development conference “Microbiome Connect USA 2024”. Spanning 3 days the event promised the chance to connect with the microbiome field, and learn about its latest...
Introduction South Korea has emerged as a leading hub for innovative microbiome research and development, with a thriving biopharmaceutical industry and cutting-edge research institutions. In this article, we will highlight seven South Korean microbiome developers that are poised to make significant advancements in 2024. Korean Microbiome Developers Genome & Co Located in Seongnam-Si, Genome +...
Last month, Microbiome Movement returned to Boston for its 8th Drug Development summit. With 2023’s multiple regulatory approvals for C. difficile microbiome treatments, the event set out to platform microbial-based approaches beyond the condition. The event consisted of a three-track agenda divided across “Discovery & Pre-clinical”, “Translational & Clinical”, and “Manufacturing & Process development” tracks...
Introduction Last month, Biose industrie had the privilege of speaking at Microbiome Connect: Asia. The two-day congress took place in Seoul, Korea, and was attended by microbiome enthusiasts across academia and industry alike. Given the rapidly growing APAC microbiome market, Biose were thrilled to hear from APAC voices on topics ranging from regulatory firsts to...
Aurillac, France, May 29th, 2023 Biose Industrie, a contract development manufacturing organisation (CDMO) and a world-leader of live biotherapeutic product (LBP) process development and production, and SBT instruments, a bacteria-focused state-of-the-art industrial equipment supplier, announced a collaboration to implement rapid viable cell counts within Biose’s manufacturing process. The emerging field of live biotherapeutics faces...
Biose Industries takes pride in showcasing its partners and drawing attention to the fantastic work they are doing. We sat down with Alveolus Bio with whom we are working to bring their inhalable live biotherapeutic (LBP) to market. Read on to understand the challenges in developing an LBP for lung indications, the origins of Alveolus’...
The Pharmabiotics Conference & Partnering returned for 2023, bringing together cutting-edge microbiome researchers and drug developers. In the heart of Lyon 220 microbiome stakeholders gathered to explore key topics facing the field: from regulatory hurdles to considerations for spinning out. The event featured three panel discussions on developing a drug from “concept to consortia”, the...
Access the Presentation Slides Here
Aurillac, France, March 2nd, 2023 Biose Industrie, a contract development manufacturing organisation (CDMO) and a world-leader of live biotherapeutic product (LBP) process development and production, announced today their plan to open a laboratory in the heart of Boston, Massachusetts, later this year. Following Biose Industries overwhelming success in LBP process development and manufacturing throughout...
L-GAM and the French State through the “French Tech Souveraineté” scheme have signed a purchase agreement with the aim of acquiring joint control of Biose Industrie, a world leader in the development and production of Live Biotherapeutic Products (LBPs), in order to support the group in a new phase of its development. Biose Industrie is...
